The absence of tumor-infiltrating lymphocytes negatively impacts the response to chemotherapy and prognosis in all subtypes of breast cancer. Therapies that stimulate a proinflammatory environment may help improve the response to standard treatments and also to immunotherapies such as checkpoint inhibitors. Newcastle disease virus (NDV) shows oncolytic activity, as well as immune modulating potential, in the treatment of breast cancer in vitro and in vivo; however, its potential to enhance tumor-infiltrating immune cells in breast cancer has yet to be evaluated. Since spontaneous canine mammary tumors represent a translational model of human breast cancer, we conducted this proof-of-concept study, which could provide a rationale for further investigating NDV-MLS as immunotherapy for mammary cancer. Six female companion dogs with spontaneous mammary cancer received a single intravenous and intratumoral injection of oncolytic NDV-MLS. Immune cell infiltrates were evaluated by histology and immunohistochemistry in the stromal, intratumoral, and peritumoral compartments on day 6 after viral administration. Increasing numbers of immune cells were documented post-viral treatment, mainly in the peritumoral compartment, where plasma cells and CD3+ and CD3-/CD79- lymphocytes predominated. Viral administration was well tolerated, with no significant adverse events. These findings support additional research on the use of NDV-MLS immunotherapy for mammary cancer.
The involvement of the nervous system in the development of cancer is controversial. Several authors have shown opinions and conflicting evidence that support the early effect of the nervous system on the carcinogenic process. For about a century, research has not been enough, questions remain open, ideas are not discarded, and although more research is still needed to answer all the questions, there is now enough evidence to support the theories and give hope of finding one more possible form of treatment. It is clear that malignant neoplasms have endogenous characteristics that allow them to establish and progress. Some of these characteristics known as hallmarks of cancer, are damage mechanisms in the pathology but necessary during other physiological processes which show some nerve dependence. The nervous system communicates with the whole organism, regulating physiological processes necessary to respond to external stimuli and for the maintenance of homeostasis. The modification of nerve activity could generate an overload and deregulate the state of cellular and tissue homeostasis; this could drive cancer development. In this review, we will address the issue in an evidence-oriented manner that supports that the nervous system is able to participate in the initial and progressive process of carcinogenesis by inducing biochemical, physiological, and cellular modifications involved in the hallmarks of cancer.
Lung transplantation requires optimization of donor’s organ use through ex vivo lung perfusion (EVLP) to avoid primary graft dysfunction. Biomarkers can aid in organ selection by providing early evidence of suboptimal lungs during EVLP and thus avoid high-risk transplantations. However, predictive biomarkers of pulmonary graft function such as endothelin-converting enzyme (ECE-1) and vascular endothelial growth factor (VEGF) have not been described under EVLP with standard prolonged hypothermic preservation, which are relevant in situations where lung procurement is difficult or far from the transplantation site. Therefore, this study is aimed at quantifying ECE-1 and VEGF, as well as determining their association with hemodynamic, gasometric, and mechanical ventilatory parameters in a swine model of EVLP with standard prolonged hypothermic preservation. Using a protocol with either immediate (I-) or delayed (D-) initiation of EVLP, ECE-1 levels over time were found to remain constant in both study groups ( RM-ANOVA), while the VEGF protein was higher after prolonged preservation, but it decreased throughout EVLP ( RM-ANOVA). Likewise, hemodynamic, gasometric, mechanical ventilatory, and histological parameters had a tendency to better results after 12 hours of hypothermic preservation in the delayed infusion group.
Cancer encompasses a group of diseases characterized by the proliferation of abnormal cells, which divide, grow and can spread uncontrollably in any part of the body. These cells form masses of tissue called tumors or neoplasms, causing problems in the area of the body where they develop; besides, they can spread to other parts of the body. Cancer cells differ from normal cells in many ways: they are less specialized cells, they ignore signals to stop their proliferation and to die when necessary, they influence normal cells, they have the ability to evade the immune system, they grow uncontrollably, and they become invasive. Cancer is considered a preventable disease, adopting strategies to avoid risk factors. In addition to being preventable, some types of cancer can be detected early. The purpose of early detection is to identify the tumor when it is located in the organ of origin, before it spreads to other organs, or to detect precancerous lesions (benign tumors). The correct diagnosis of cancer is essential to be able to establish an adequate and effective treatment. There are a lot of myths and misconceptions about cancer, including that this disease is synonymous with death.
Polymerised type I collagen (polymerised collagen) and pirfenidone (PFD) reduce fibrosis. However, their use as pharmacological monotherapy for tracheal stenosis (TS) has not been evaluated. This study aimed to evaluate the effects of polymerised collagen or PFD, used either as monotherapy for TS, or in combination with tracheal resection (TRE) on the development of restenosis (RTS), apoptotic body (AB) formation, production of profibrotic proteins, ITGβ1 expression and metalloproteinase (MMP) expression in a rat model of TS. Eighty Wistar rats underwent TS. Forty received monotherapy (treatment A) with: saline solution (SS), mitomycin C (MMC), polymerised collagen, or PFD. The other forty received TRE combined with the pharmacological treatment (treatment B). They were clinically evaluated. Four weeks after treatment, AB formation, ITGβ1, TGF-β, profibrotic proteins, and MMPs expression were assessed in TS tissue and post-TRE tissue. Our findings showed that treatment A with polymerised collagen or PFD did not reverse TS but halted its progression, reduced the expression of profibrotic proteins, ITGβ1 and MMP-9, and increased AB and MMP-1. Treatment B promoted normal tracheal healing and prevented RTS. We conclude that the use of polymerised collagen or PFD as monotherapy does not reverse TS. However, they halt disease progression by modulating the production of profibrotic factors. In combination with TRE, these agents promote favourable tracheal healing and prevent RTS.
Asociación histológica con factores potenciales de riesgo y tiempo de sobrevida en el tumor mamario canino
About Me
Laura P. Romero is a Doctor in Veterinary Medicine (DVM) who graduated from the Faculty of Veterinary Medicine and Zootechnics (FMVZ) of the UNAM. She completed a residency in Comparative Pathology at the General Hospital of Mexico. She obtained the degree of Master in Veterinary Sciences (Veterinary Pathology) at the FMVZ-UNAM and a PhD degree in Biomedical Sciences from the University of Guelph, in Canada. She also obtained a Master's degree in Molecular Oncology from the National Cancer Research Center and the Center for Biosanitary Studies, Spain, and the European School of Oncology. Likewise, she completed a Diploma in Veterinary Medicine Teaching at the UNAM.
Laura is a full-time professor at the FMVZ-UNAM where she teaches various courses including: General Veterinary Pathology at the undergraduate level, while at the graduate level she teaches the courses of Mechanisms of Disease, Systemic Pathology and Diagnostic Cytopathology at the master's and doctoral levels.
Laura´s current research focuses on: Characterization of nerve sheath patterns in mammary tumors of dogs; characterization of infiltrating leukocytes in mammary tumors of dogs; characterization of feline lymphoma and its relationship with feline viral leukemia virus.
She belongs to the Mexican Society of Veterinary Pathologists A.C. (SMPV) and to the Mexican Association of Veterinary Oncology (AMONCOVET).
Laura P. Romero is a Doctor in Veterinary Medicine (DVM) who graduated from the Faculty of Veterinary Medicine and Zootechnics (FMVZ) of the UNAM. She completed a residency in Comparative Pathology at the General Hospital of Mexico. She obtained the degree of Master in Veterinary Sciences (Veterinary Pathology) at the FMVZ-UNAM and a PhD degree in Biomedical Sciences from the University of Guelph, in Canada. She also obtained a Master's degree in Molecular Oncology from the National Cancer Research Center and the Center for Biosanitary Studies, Spain, and the European School of Oncology. Likewise, she completed a Diploma in Veterinary Medicine Teaching at the UNAM.
Laura is a full-time professor at the FMVZ-UNAM where she teaches various courses including: General Veterinary Pathology at the undergraduate level, while at the graduate level she teaches the courses of Mechanisms of Disease, Systemic Pathology and Diagnostic Cytopathology at the master's and doctoral levels.
Laura´s current research focuses on: Characterization of nerve sheath patterns in mammary tumors of dogs; characterization of infiltrating leukocytes in mammary tumors of dogs; characterization of feline lymphoma and its relationship with feline viral leukemia virus.
She belongs to the Mexican Society of Veterinary Pathologists A.C. (SMPV) and to the Mexican Association of Veterinary Oncology (AMONCOVET).